23Feb 2023
Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue‐specific insulin sensitivity in patients with early‐stage type 2 diabetes with non‐alcoholic fatty liver disease: A prospective randomized study

Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue‐specific insulin sensitivity in patients with early‐stage type 2 diabetes with non‐alcoholic fatty liver disease: A prospective randomized study

This study aimed to compare the effects of SGLT2 inhibitors and dipeptidyl peptidase‐4 inhibitors on ectopic fat accumulation and tissue-specific insulin sensitivity in patients with type 2 diabetes and non-alcoholic fatty liver disease. 44 patients were enrolled and randomly assigned to receive either empagliflozin or sitagliptin for 12 weeks. The primary endpoint was the change in intrahepatic lipid content. The study found that empagliflozin significantly improved hepatic steatosis compared to sitagliptin, and this may protect against subsequent hepatic insulin resistance. It suggests that early administration of SGLT2 inhibitors is preferable for T2D patients with NAFLD.

  • #endo-diabetology

Like

Save

Share